Patents
Literature
8 results about "Wee1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Wee1 is a nuclear kinase belonging to the Ser/Thr family of protein kinases in the fission yeast Schizosaccharomyces pombe (S. pombe). Wee1 has a molecular mass of 96 kDa and it is a key regulator of cell cycle progression. It influences cell size by inhibiting the entry into mitosis, through inhibiting Cdk1. Wee1 has homologues in many other organisms, including mammals.
Use of a protein kinase inhibitor for the preparation of a medicament for inhibiting uterine leiomyosarcoma
Disclosed is an application of a protein kinase inhibitor in preparation of a medicine for inhibiting uterine leiomyosarcoma, wherein the protein kinase inhibitor can effectively inhibit tumor growth in vitro and in vivo, and has better efficacy and safety compared with traditional chemotherapy. The protein kinase is one of the following: Wee1-like protein kinase, cyclin-dependent kinase 1, serine / threonine protein kinase 1 and serine / threonine protein kinase ATR.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL
Dihydroimidazopyrimidopyrimidinones and uses thereof
Provided are compounds of Formula I, or stereoisomers, tautomers, N-oxides, hydrates, solvates, isotopically labeled compounds, or pharmaceutically acceptable salts thereof, or mixtures thereof. Compounds of Formula I are inhibitors of Wee1 kinase. Thus, these compounds are useful in the treatment of diseases caused by abnormal Weel activity. (I).
Owner:IMPACT THERAPEUTICS (SHANGHAI) INC +1
Combination therapy comprising a myt1 inhibitor and a weel inhibitor
PendingCN122121880AOrganic active ingredientsAntineoplastic agentsDosing regimenEnzyme Inhibitor Agent
The present application relates to the use of a combination of a Myt1 inhibitor and a Wee1 inhibitor in the treatment of cancer or induction of cell death. The synergistic effect of this combination results in a sub-therapeutic dosage or reduced dosing regimen of the Myt1 inhibitor, the Wee1 inhibitor, or both, relative to monotherapy with the Myt1 inhibitor or the Wee1 inhibitor alone.
Owner:REPARE THERAPEUTICS INC
Wee1 inhibitors and methods for treating cancer
PCT designated stageWO2026112362A1Organic chemistryAntineoplastic agentsDiseasePharmaceutical medicine
Compounds of general Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
Owner:RECURIUM IP HLDG LLC
Wee1 inhibitor and use thereof
Provided are a new class of compounds having a WEE1 inhibitory effect and as represented by formula I, and the use thereof in the preparation of a drug.
Owner:JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD
Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase
Owner:ACRIVON THERAPEUTICS INC
